drugset
drugset / Trial / NCT03952143

A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes

NCT03952143 ↗

Phase 3 Completed 628 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to see if LY900014 compared to insulin lispro (Humalog), both in combination with insulin glargine or insulin degludec, is safe and effective in participants with type 2 diabetes (T2D).

Timeline

Start
2019-05-27
Primary completion
2021-01-20
Completion
2021-01-20

Drugs

EvaluationDrugModalityDoseRoute
Comparator Insulin Lispro Protein / enzyme biologic — Subcutaneous
Background insulin degludec Protein / enzyme biologic — Subcutaneous
Background insulin glargine Protein / enzyme biologic — Subcutaneous

Indications

type 2 diabetes mellitus